Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

MK-7684A con o sin otras terapias contra el cáncer en participantes con tumores sólidos seleccionados (MK-7684A-005) (KEYVIBE-005)

3 de septiembre de 2026 actualizado por: Merck Sharp & Dohme LLC

Un estudio multicéntrico, abierto, de canasta de fase 2 de MK-7684A, una coformación de vibostolimab (MK-7684) con pembrolizumab (MK-3475), con o sin otras terapias contra el cáncer en participantes con tumores sólidos seleccionados

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

611

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Berlin, Alemania, 12203
        • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Alemania, 69120
        • Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)
      • Tübingen, Baden-Wurttemberg, Alemania, 72076
        • Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne
    • Bavaria
      • München, Bavaria, Alemania, 81337
        • Klinikum der Universität München Großhadern ( Site 1176)
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Alemania, 40225
        • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)
    • Ontario
      • Kingston, Ontario, Canadá, K7L 2V7
        • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)
      • Toronto, Ontario, Canadá, M5G 2M9
        • Princess Margaret Cancer Centre ( Site 1056)
    • Araucania
      • Temuco, Araucania, Chile, 4800827
        • James Lind Centro de Investigacion del Cancer ( Site 1404)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chile, 7500921
        • FALP-UIDO ( Site 1401)
      • Santiago, Region M. de Santiago, Chile, 7510032
        • Oncovida ( Site 1405)
      • Santiago, Region M. de Santiago, Chile, 8420383
        • Bradfordhill-Clinical Area ( Site 1402)
    • Antioquia
      • Medellín, Antioquia, Colombia, 050030
        • Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)
    • Atlántico
      • Barranquilla, Atlántico, Colombia, 080020
        • Clinica de la Costa S.A.S. ( Site 1421)
    • Cundinamarca
      • Bogotá, Cundinamarca, Colombia, 111511
        • Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)
    • Risaralda Department
      • Pereira, Risaralda Department, Colombia, 661001
        • Oncologos del Occidente ( Site 1424)
    • Santander Department
      • Piedecuesta, Santander Department, Colombia, 681017
        • Fundación Cardiovascular de Colombia ( Site 1423)
      • Seoul, Corea del Sur, 03080
        • Seoul National University Hospital-Internal Medicine ( Site 1312)
      • Seoul, Corea del Sur, 03722
        • Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)
      • Seoul, Corea del Sur, 05505
        • Asan Medical Center ( Site 1313)
      • Madrid, España, 28027
        • Clinica Universidad de Navarra-Medical Oncology ( Site 1118)
      • Seville, España, 41013
        • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)
    • Barcelona
      • Hospitalet, Barcelona, España, 08907
        • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)
    • Madrid
      • Pozuelo de Alarcón, Madrid, España, 28223
        • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, España, 28034
        • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)
    • Alaska
      • Anchorage, Alaska, Estados Unidos, 99508
        • Alaska Womens Cancer Care ( Site 1016)
    • California
      • Duarte, California, Estados Unidos, 91010
        • City of Hope Comprehensive Cancer Center ( Site 1001)
      • Orange, California, Estados Unidos, 92868-3201
        • University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48201
        • Karmanos Cancer Institute ( Site 1007)
    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Memorial Sloan Kettering - Basking Ridge ( Site 1023)
      • Middletown, New Jersey, Estados Unidos, 07748
        • Memorial Sloan Kettering - Monmouth ( Site 1022)
      • Montvale, New Jersey, Estados Unidos, 07645
        • Memorial Sloan Kettering - Bergen ( Site 1025)
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Memorial Sloan Kettering- Commack ( Site 1021)
      • Harrison, New York, Estados Unidos, 10604
        • Memorial Sloan Kettering - Westchester ( Site 1020)
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan Kettering Cancer Center ( Site 1002)
      • Uniondale, New York, Estados Unidos, 11553
        • Memorial Sloan Kettering - Nassau ( Site 1026)
    • Oklahoma
      • Tulsa, Oklahoma, Estados Unidos, 74146
        • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)
    • South Dakota
      • Sioux Falls, South Dakota, Estados Unidos, 57104
        • Sanford Cancer Center-Gynecologic Oncology ( Site 1015)
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Houston Methodist Hospital ( Site 1017)
      • Paris, Francia, 75248
        • Institut Curie ( Site 1152)
    • Auvergne-Rhône-Alpes
      • Lyon, Auvergne-Rhône-Alpes, Francia, 69373 Cedex 08
        • CENTRE LEON BERARD-Medical oncology ( Site 1151)
    • Cote-d Or
      • Dijon, Cote-d Or, Francia, 21079
        • Centre Georges François Leclerc ( Site 1155)
    • Herault
      • Montpellier, Herault, Francia, 34298
        • Institut Regional du Cancer Montpellier ( Site 1157)
    • Paris
      • Villejuif, Paris, Francia, 94800
        • Gustave Roussy-medicine departement ( Site 1153)
    • Vaucluse
      • Avignon, Vaucluse, Francia, 84000
        • Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus-Oncology ( Site 1141)
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center-Oncology ( Site 1142)
      • Ramat Gan, Israel, 5265601
        • Sheba Medical Center-ONCOLOGY ( Site 1144)
      • Tel Aviv, Israel, 6423906
        • Sourasky Medical Center-Oncology ( Site 1143)
      • Milan, Italia, 20141
        • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
      • Naples, Italia, 80131
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)
    • Lazio
      • Rome, Lazio, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)
    • Lombardy
      • Milan, Lombardy, Italia, 20132
        • Ospedale San Raffaele-Oncologia Medica ( Site 1135)
    • Milano
      • Rozzano, Milano, Italia, 20089
        • Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)
      • Osaka, Japón, 541-8567
        • Osaka International Cancer Institute ( Site 1323)
      • Tokyo, Japón, 104-0045
        • National Cancer Center Hospital ( Site 1322)
    • Aichi-ken
      • Nagoya, Aichi-ken, Japón, 464-8681
        • Aichi Cancer Center Hospital ( Site 1324)
    • Chiba
      • Kashiwa, Chiba, Japón, 277-8577
        • National Cancer Center Hospital East ( Site 1321)
    • North Holland
      • Amsterdam, North Holland, Países Bajos, 1066CX
        • Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)
    • South Holland
      • Rotterdam, South Holland, Países Bajos, 3015 GD
        • Erasmus Medisch Centrum-Medical Oncology ( Site 1122)
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polonia, 80-952
        • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)
    • West Pomeranian Voivodeship
      • Koszalin, West Pomeranian Voivodeship, Polonia, 75-581
        • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)
      • Tainan, Taiwán, 704
        • NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)
      • Taipei, Taiwán, 10002
        • National Taiwan University Hospital-Oncology ( Site 1301)
      • Taipei, Taiwán, 10449
        • Mackay Memorial Hospital ( Site 1305)
      • Taoyuan, Taiwán, 333
        • Chang Gung Medical Foundation-Linkou Branch ( Site 1304)
      • Adana, Turquía (Türkiye), 01250
        • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)
      • Ankara, Turquía (Türkiye), 06230
        • Hacettepe Universitesi-oncology hospital ( Site 1209)
      • Ankara, Turquía (Türkiye), 06800
        • Ankara City Hospital-Medical Oncology ( Site 1202)
      • Edirne, Turquía (Türkiye), 22030
        • Trakya University-Medical Oncology ( Site 1207)
      • Istanbul, Turquía (Türkiye), 34303
        • Acibadem Universitesi Atakent Hastanesi ( Site 1208)
      • Istanbul, Turquía (Türkiye), 34722
        • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)
    • Istanbul
      • Istanbul- Fatih, Istanbul, Turquía (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa ( Site 1203)

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:

    • Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
    • Endometrial cancer
    • Head and neck squamous cell carcinoma (HNSCC)
    • Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
    • Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
    • Triple-negative breast cancer (TNBC)
    • Hepatocellular carcinoma (HCC)
    • Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
    • Ovarian cancer
    • Gastric cancer
  • Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.

  • Adequately controlled blood pressure (BP) with or without antihypertensive medications.

  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).

  • Male participants must agree to follow contraceptive guidance.

  • Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.

  • Adequate organ function.

Exclusion Criteria:

  • History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
  • Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
  • Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Active infection requiring systemic therapy.
  • Concurrent active hepatitis B and hepatitis C virus infection.
  • History of allogenic tissue/solid organ transplant.
  • Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Pembrolizumab/Vibostolimab Co-Formulation

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Otros nombres:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®
Experimental: Pembrolizumab

Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles.

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®
Experimental: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Otros nombres:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Otros nombres:
  • E7080
  • Lenvima
  • MK-7902
Experimental: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Otros nombres:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®

Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Otros nombres:
  • E7080
  • Lenvima
  • MK-7902
Experimental: Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Otros nombres:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®

5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

Otros nombres:
  • 5-FU
  • Fluracilo

Cisplatin administered via IV infusion

Otros nombres:
  • Platinol
  • platino cis
Experimental: Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel.

Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Otros nombres:
  • MK-7684A

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®

Paclitaxel administered via IV infusion at investigator's choice of dose

Otros nombres:
  • Taxol
  • Abraxane
  • Anzatax
Experimental: Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®

Cisplatin administered via IV infusion

Otros nombres:
  • Platinol
  • platino cis

Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

Experimental: Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab.

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®

Paclitaxel administered via IV infusion at investigator's choice of dose

Otros nombres:
  • Taxol
  • Abraxane
  • Anzatax

Carboplatin administered via IV infusion at investigator's choice of dose and frequency

For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

Experimental: Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin

Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin.

Pembrolizumab 200 mg administered via IV infusion Q3W.

Otros nombres:
  • MK-3475
  • KEYTRUDA®

Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

Oxaliplatin administered via IV infusion Q3W up to 35 cycles

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
Periodo de tiempo: Up to approximately 24 months

ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen & Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
Periodo de tiempo: Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented.

Up to approximately 24 months
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Periodo de tiempo: Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented.

Up to approximately 24 months
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
Periodo de tiempo: 9 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

9 months
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
Periodo de tiempo: 12 months

PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented.

12 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Survival (OS) in Participants With Selected Solid Tumors
Periodo de tiempo: Up to approximately 46 months

For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented.

Up to approximately 46 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Periodo de tiempo: Up to approximately 46 months

PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented.

Up to approximately 46 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1
Periodo de tiempo: Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1.

Up to approximately 46 months
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Periodo de tiempo: Up to approximately 46 months

For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented.

Up to approximately 46 months
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1
Periodo de tiempo: Up to approximately 24 months

ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1
Periodo de tiempo: Up to approximately 24 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented.

Up to approximately 24 months
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1
Periodo de tiempo: Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented.

Baseline and up to Week 12
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1
Periodo de tiempo: Baseline and up to Week 12

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented.

Baseline and up to Week 12
Number of Participants Who Experienced One or More Adverse Events (AEs)
Periodo de tiempo: Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm.

Up to approximately 46 months
Number of Participants Who Discontinued Study Intervention Due to an AE
Periodo de tiempo: Up to approximately 46 months

An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm.

Up to approximately 46 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Medical Director, Merck Sharp & Dohme LLC

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de septiembre de 2021

Finalización primaria (Actual)

5 de agosto de 2025

Finalización del estudio (Actual)

5 de agosto de 2025

Fechas de registro del estudio

Enviado por primera vez

10 de agosto de 2021

Primero enviado que cumplió con los criterios de control de calidad

10 de agosto de 2021

Publicado por primera vez (Actual)

16 de agosto de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de septiembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 7684A-005
  • MK-7684A-005 (Otro identificador: MSD)
  • jRCT2031210335 (Identificador de registro: jRCT)
  • KEYVIBE-005 (Otro identificador: MSD)
  • 2021-001009-56 (Número EudraCT)
  • U1111-1291-4290 (Identificador de registro: UTN)
  • 2023-505284-36-00 (Identificador de registro: EU CT)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir